Skip to content
TrialScanner

NCT04987671

Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

Phase 1/Phase 2Unknown statusAMLXLead

Registry record

Lead sponsor
Amylyx Pharmaceuticals Inc.
Conditions
ALS
Primary completion
May 11, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04987671 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04987671: Pharmacokinetic and Pharmacod... | TrialScanner